{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:59:22Z","timestamp":1794092362686,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Erlangen","id":[{"id":"https:\/\/ror.org\/0030f2a11","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Ovarian cancer is frequently associated with\n                      <jats:italic>gBRCA1\/2<\/jats:italic>\n                      mutations, which also confer a high lifetime risk of breast cancer in non-affected patients. While risk-reducing salpingo-oophorectomy (RRSO) is established in hereditary breast and ovarian cancer prevention, the recommendation for risk-reducing bilateral mastectomy (RRBM) remains unclear in\n                      <jats:italic>gBRCA1\/2<\/jats:italic>\n                      mutovarian cancer patients due to high recurrence rates and limited survival. This study evaluates the preventive strategies of these patients in a real-world setting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included 49 patients with\n                      <jats:italic>gBRCA1\/2mut<\/jats:italic>\n                      HGSC treated at the Hereditary Breast and Ovarian Cancer Centre, University Hospital Erlangen, between 2012 and 2024. Clinical, pathological, treatment-related, and genetic data were collected and analyzed from electronic records.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 49 patients with\n                      <jats:italic>gBRCAmut<\/jats:italic>\n                      HGSC, 44 out of 49 did not undergo a RRBM during follow-up. Intensified breast cancer surveillance was recommended to 33 patients. Although 19 out of 49 patients were formally recommended a RRBM, only two proceeded with the preventive option. Three additional patients chose the surgery driven by the diagnosis of metachronous breast cancer. 80% of the operations occurred\u2009&gt;\u200960 months after ovarian cancer diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In patients with\n                      <jats:italic>gBRCA1\/2mut<\/jats:italic>\n                      and a history of HGSC, RRBM is rarely chosen. Most patients prefer an intensified surveillance program. Due to low metachronous breast cancer rate in follow up care, RRBM seems to be an option just for long-term survivors. Individual patient preferences play a crucial role in the management strategy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-026-06543-4","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:27:29Z","timestamp":1782030449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Breast cancer prevention in patients with gBRCA-mutated ovarian cancer"],"prefix":"10.1007","volume":"152","author":[{"given":"Niklas","family":"Amann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Kr\u00fcckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Br\u00fcckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gocke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Heindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin C.","family":"Hack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Stumpf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Emons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias W.","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"H\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"issue":"05","key":"6543_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1055\/a-1933-9469","volume":"17","author":"N Amann","year":"2023","unstructured":"Amann N et al (2023) Heredit\u00e4re Karzinome in der Gyn\u00e4kologie. Frauenheilkund up2date 17(05):477\u2013493","journal-title":"Frauenheilkund up2date"},{"issue":"1","key":"6543_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00432-025-06388-3","volume":"152","author":"N Amann","year":"2025","unstructured":"Amann N et al (2025) Quality of care before and after initial certification at a German certified hereditary breast and ovarian cancer center. J Cancer Res Clin Oncol 152(1):13","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"6543_CR3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1200\/JCO-25-01648","volume":"44","author":"AI Apostol","year":"2026","unstructured":"Apostol AI et al (2026) Risk of breast cancer after ovarian cancer in women with a pathogenic\/likely pathogenic variant in BRCA1 or BRCA2. J Clin Oncol 44(10):883\u2013892","journal-title":"J Clin Oncol"},{"issue":"09","key":"6543_CR4","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1055\/a-1222-0042","volume":"80","author":"B Ataseven","year":"2020","unstructured":"Ataseven B et al (2020) Prevalence of BRCA1 and BRCA2 mutations in patients with primary ovarian cancer\u2014Does the german checklist for detecting the risk of hereditary breast and ovarian cancer adequately depict the need for consultation? Geburtshilfe Frauenheilkd 80(09):932\u2013940","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"4","key":"6543_CR5","first-page":"161","volume":"94","author":"MW Beckmann","year":"1997","unstructured":"Beckmann MW et al (1997) Hochrisikofamilien mit Mamma- und Ovarialkarzinomen: M\u00f6glichkeiten der Beratung, genetischen Analyse und Fr\u00fcherkennung. Dtsch Arztebl Int 94(4):161","journal-title":"Dtsch Arztebl Int"},{"issue":"2","key":"6543_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00117-020-00797-w","volume":"61","author":"U Bick","year":"2021","unstructured":"Bick U (2021) Intensivierte Fr\u00fcherkennung mittels Magnetresonanztomographie in der Hochrisikosituation. Radiologe 61(2):150\u2013158","journal-title":"Radiologe"},{"issue":"1","key":"6543_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10549-019-05152-9","volume":"175","author":"U Bick","year":"2019","unstructured":"Bick U et al (2019) High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. Breast Cancer Res Treat 175(1):217\u2013228","journal-title":"Breast Cancer Res Treat"},{"issue":"26","key":"6543_CR8","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26):2473\u20132483","journal-title":"N Engl J Med"},{"issue":"14","key":"6543_CR9","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jama.2025.9495","volume":"334","author":"G Caruso","year":"2025","unstructured":"Caruso G, Weroha SJ, Cliby W (2025) Ovarian cancer: a review. Jama 334(14):1278\u20131291","journal-title":"Jama"},{"issue":"9","key":"6543_CR10","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967\u2013975","journal-title":"JAMA"},{"issue":"7","key":"6543_CR11","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/cncr.27842","volume":"119","author":"SM Domchek","year":"2013","unstructured":"Domchek SM et al (2013) Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer 119(7):1344\u20131348","journal-title":"Cancer"},{"issue":"07","key":"6543_CR12","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1055\/a-2622-0684","volume":"85","author":"J Emons","year":"2025","unstructured":"Emons J et al (2025) Update gynecologic malignancies 2025\u2014expert opinion on systemic therapy for early and advanced gynecological cancers. Geburtshilfe Frauenheilkd 85(07):736\u2013745","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"9","key":"6543_CR13","doi-asserted-by":"publisher","first-page":"101172","DOI":"10.1016\/j.gim.2024.101172","volume":"26","author":"DG Evans","year":"2024","unstructured":"Evans DG et al (2024) Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: lower rates for 5 years post chemotherapy. Genet Med 26(9):101172","journal-title":"Genet Med"},{"issue":"2","key":"6543_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1148\/radiol.2017171665","volume":"287","author":"Y Gao","year":"2018","unstructured":"Gao Y et al (2018) What happens after a diagnosis of high-risk breast lesion at stereotactic vacuum-assisted biopsy? An observational study of postdiagnosis management and imaging adherence. Radiology 287(2):423\u2013431","journal-title":"Radiology"},{"issue":"10","key":"6543_CR15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A et al (2023) Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34(10):833\u2013848","journal-title":"Ann Oncol"},{"issue":"1","key":"6543_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-16849-4","volume":"23","author":"LM Gro\u00dfmann","year":"2023","unstructured":"Gro\u00dfmann LM, Napierala H, Herrmann WJ (2023) Differences in breast and cervical cancer screening between West and East Germany: a secondary analysis of a German nationwide health survey. BMC Public Health 23(1):1931","journal-title":"BMC Public Health"},{"issue":"1","key":"6543_CR17","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1186\/s12889-023-16589-5","volume":"23","author":"M Heinig","year":"2023","unstructured":"Heinig M et al (2023) German mammography screening program: adherence, characteristics of (non-)participants and utilization of non-screening mammography-a longitudinal analysis. BMC Public Health 23(1):1678","journal-title":"BMC Public Health"},{"issue":"1","key":"6543_CR18","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1038\/ncomms4156","volume":"5","author":"KL Kanchi","year":"2014","unstructured":"Kanchi KL et al (2014) Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun 5(1):3156","journal-title":"Nat Commun"},{"issue":"7","key":"6543_CR19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/jmedgenet-2015-103672","volume":"53","author":"K Kast","year":"2016","unstructured":"Kast K et al (2016) Prevalence of BRCA1\/2 germline mutations in 21\u2005401 families with breast and ovarian cancer. J Med Genet 53(7):465\u2013471","journal-title":"J Med Genet"},{"issue":"1","key":"6543_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ygyno.2018.05.011","volume":"150","author":"J Kotsopoulos","year":"2018","unstructured":"Kotsopoulos J et al (2018) Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 150(1):85\u201391","journal-title":"Gynecol Oncol"},{"issue":"23","key":"6543_CR21","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402\u20132416","journal-title":"JAMA"},{"key":"6543_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17030977","author":"J Lipscomb","year":"2020","unstructured":"Lipscomb J et al (2020) Improving screening uptake among breast cancer survivors and their first-degree relatives at elevated risk to breast cancer: results and implications of a randomized study in the State of Georgia. Int J Environ Res Public Health. https:\/\/doi.org\/10.3390\/ijerph17030977","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"6543_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1056\/NEJM200107193450301","volume":"345","author":"H Meijers-Heijboer","year":"2001","unstructured":"Meijers-Heijboer H et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345(3):159\u2013164","journal-title":"N Engl J Med"},{"key":"6543_CR24","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-18343-0","author":"A Melanson","year":"2025","unstructured":"Melanson A et al (2025) Uptake of risk reducing mastectomy in older BRCA1\/2 and PALB2 carriers undergoing genetic testing after 60 years of age. Annals of Surgical Oncology. https:\/\/doi.org\/10.1245\/s10434-025-18343-0","journal-title":"Annals of Surgical Oncology"},{"issue":"10290","key":"6543_CR25","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","volume":"397","author":"U Menon","year":"2021","unstructured":"Menon U et al (2021) Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 397(10290):2182\u20132193","journal-title":"Lancet"},{"issue":"1","key":"6543_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","volume":"121","author":"K Metcalfe","year":"2019","unstructured":"Metcalfe K et al (2019) International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer 121(1):15\u201321","journal-title":"Br J Cancer"},{"issue":"2","key":"6543_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41416-023-02503-8","volume":"130","author":"K Metcalfe","year":"2024","unstructured":"Metcalfe K et al (2024) Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis. Br J Cancer 130(2):269\u2013274","journal-title":"Br J Cancer"},{"issue":"26","key":"6543_CR28","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484\u20132496","journal-title":"N Engl J Med"},{"key":"6543_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.dnarep.2014.01.009","volume":"17","author":"SK Radhakrishnan","year":"2014","unstructured":"Radhakrishnan SK, Jette N, Lees-Miller SP (2014) Non-homologous end joining: emerging themes and unanswered questions. DNA Repair 17:2\u20138","journal-title":"DNA Repair"},{"issue":"25","key":"6543_CR30","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381(25):2416\u20132428","journal-title":"N Engl J Med"},{"issue":"6","key":"6543_CR31","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","volume":"22","author":"TR Rebbeck","year":"2004","unstructured":"Rebbeck TR et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6):1055\u20131062","journal-title":"J Clin Oncol"},{"issue":"1","key":"6543_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","volume":"14","author":"BM Reid","year":"2017","unstructured":"Reid BM, Permuth JB, Sellers TA (2017) Epidemiology of ovarian cancer: a review. Cancer Biol Med 14(1):9\u201332","journal-title":"Cancer Biol Med"},{"key":"6543_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020470","author":"P Salas Bol\u00edvar","year":"2025","unstructured":"Salas Bol\u00edvar P et al (2025) Prognostic factors after the first recurrence of ovarian cancer. J Clin Med. https:\/\/doi.org\/10.3390\/jcm14020470","journal-title":"J Clin Med"},{"issue":"2","key":"6543_CR34","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ygyno.2019.05.017","volume":"154","author":"C Salyer","year":"2019","unstructured":"Salyer C et al (2019) Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations. Gynecol Oncol 154(2):374\u2013378","journal-title":"Gynecol Oncol"},{"issue":"8","key":"6543_CR35","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00761-025-01757-6","volume":"31","author":"A Schultz","year":"2025","unstructured":"Schultz A et al (2025) Faktenblatt: epidemiologie des ovarialkarzinoms in Deutschland. Die Onkologie 31(8):739\u2013745","journal-title":"Die Onkologie"},{"issue":"1","key":"6543_CR36","doi-asserted-by":"publisher","first-page":"e2449556","DOI":"10.1001\/jamanetworkopen.2024.49556","volume":"8","author":"AE Sedani","year":"2025","unstructured":"Sedani AE et al (2025) Social risks and nonadherence to recommended cancer screening among US adults. JAMA Netw Open 8(1):e2449556","journal-title":"JAMA Netw Open"},{"issue":"3","key":"6543_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 71(3):209\u2013249","journal-title":"Cancer J Clin"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06543-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06543-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06543-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:06:49Z","timestamp":1794049609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06543-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["6543"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06543-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9622476\/v1","asserted-by":"object"}]},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,21]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Faculty of Medicine at Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU) (ref. number 24-440-Br). All procedures were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Additional patient\u2019s agreement to the study was waived due to the retrospective study design, including only anonymized data analysis. There was no use of animal research within this project.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"124"}}